Tonix Pharmaceuticals Holding (TNXP) Return on Sales (2024 - 2025)
Historic Return on Sales for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to 9.68%.
- Tonix Pharmaceuticals Holding's Return on Sales fell 40600.0% to 9.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.49%, marking a year-over-year increase of 30700.0%. This contributed to the annual value of 13.54% for FY2024, which is 9000.0% down from last year.
- Tonix Pharmaceuticals Holding's Return on Sales amounted to 9.68% in Q3 2025, which was down 40600.0% from 13.69% recorded in Q2 2025.
- Tonix Pharmaceuticals Holding's 5-year Return on Sales high stood at 5.61% for Q3 2024, and its period low was 35.02% during Q2 2024.
- Moreover, its 3-year median value for Return on Sales was 8.6% (2024), whereas its average is 11.35%.
- Within the past 5 years, the most significant YoY rise in Tonix Pharmaceuticals Holding's Return on Sales was 213300bps (2025), while the steepest drop was -40600bps (2025).
- Over the past 3 years, Tonix Pharmaceuticals Holding's Return on Sales (Quarter) stood at 7.23% in 2023, then dropped by -20bps to 8.71% in 2024, then decreased by -11bps to 9.68% in 2025.
- Its Return on Sales stands at 9.68% for Q3 2025, versus 13.69% for Q2 2025 and 6.61% for Q1 2025.